Home / Market News / $PFE
fiscal.ai Corporate Catalyst Impact 65/100 ● positive

Pfizer Enters into Exclusive Licensing Agreement with Starna Therapeutics for Autoimmune Diseases

Nov 18, 2026, 12:33 PM UTC · Primary ticker $PFE

Pfizer has entered an exclusive licensing agreement with Starna Therapeutics for three pre-IND CAR-T programs targeting autoimmune diseases. This collaboration expands Pfizer's Inflammation & Immunology pipeline and leverages its RNA delivery expertise, potentially offering new treatment avenues for autoimmune conditions.

Pfizer has secured an exclusive licensing agreement with Starna Therapeutics for three pre-IND CAR-T programs focused on autoimmune diseases, excluding Greater China. This move is significant as it allows Pfizer to expand its Inflammation & Immunology pipeline with next-generation cell therapy approaches, leveraging its existing expertise in RNA delivery. For Pfizer, this represents a strategic opportunity to diversify its drug portfolio and potentially tap into a new, high-growth area within autoimmune disease treatment. While the programs are still pre-IND, indicating a long development timeline, this collaboration signals Pfizer's commitment to innovation in cell therapy. The short-term impact on Pfizer's stock might be modest given the early stage of the programs, but long-term, successful development could be a significant value driver. Traders should monitor future clinical trial announcements and regulatory milestones for these programs.

$PFE positive Expands pipeline in autoimmune diseases
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.